Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 1, 2009, Pages 115-123

  Kato, Masaki ^a,b   Fukuda, Tsuyoshi ^c   Wakeno, Masataka ^a   Okugawa, Gaku ^a   Takekita, Yoshiteru ^a   Watanabe, Syunsuke ^c   Yamashita, Megumi ^c   Hosoi, Yuka ^c   Azuma, Junichi ^c   Kinoshita, Toshihiko ^a   Serretti, Alessandro ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Depression; Pharmacogenetics; Serotonin 1A receptor; Treatment response

Indexed keywords

FLUVOXAMINE; MILNACIPRAN; PAROXETINE;

ADULT; ALLELE; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BASE SEQUENCE; DEPRESSIVE DISORDER, MAJOR; DNA PRIMERS; HUMANS; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN UPTAKE INHIBITORS;

EID: 58849161293     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30783     Document Type: Article

References (47)

1. Albert PR, Lemonde S. 2004. 5-HT1A receptors, gene repression, and depression: Guilt by association. Neuroscientist 10(6):575-593.
2. Anonymous. 2003. The International HapMap Project. Nature 426(6968):789-796.
3. Arias B, Arranz MJ, Gasto C, Catalan R, Pintor L, Gutierrez B, Kerwin RW, Fananas L. 2002. Analysis of structural polymorphisms and C-1018G promoter variant of the 5-HT(1A) receptor gene as putative risk factors in major depression. Mol Psychiatry 7(9):930-932.
4. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 2005. Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 19(2):166-172.
5. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265.
6. Cavalli Sforza L. 1994. The History and Geography of Human Genes. Princeton, New Jersey, USA: Princeton University Press.
7. Chen TJ, Yu YW, Hong CJ, Chen MC, Tsai SJ. 2004. Association analysis for the C-1019G promoter variant of the 5-HT1A receptor gene with auditory evoked potentials in major depression. Neuropsychobiology 50(4):292-295.
8. Cidis Meltzer C, Drevets WC, Price JC, Mathis CA, Lopresti B, Greer PJ, Villemagne VL, Holt D, Mason NS, Houck PR. 2001. Gender-specific aging effects on the serotonin 1A receptor. Brain Res 895(1-2):9-17.
9. Cohen J. 1988. Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates. pp. 8-14.
10. David SP, Murthy NV, Rabiner EA, Munafo MR, Johnstone EC, Jacob R, Walton RT, Grasby PM. 2005. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci 25(10):2586-2590.
11. Deckert J, Catalano M, Heils A, Di Bella D, Friess F, Politi E, Franke P, Nothen MM, Maier W, Bellodi L, et al. 1997. Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet 7(1):45-47.
12. Deng PY, Poudel SK, Rojanathammanee L, Porter JE, Lei S. 2007. Serotonin inhibits neuronal excitability by activating two-pore domain k+ channels in the entorhinal cortex. Mol Pharmacol 72(1):208-218.
13. Dubovsky SL, Thomas M. 1995. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 56(Suppl 2):38-48.
14. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. 2004. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 174(4):525-529.
15. Fava M. 2003. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649-659.
16. Fava M, Davidson KG. 1996. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19(2):179-200.
17. First MB, Spitzer RL, Gibbon M, Williams JB. 1995. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID - I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute.
18. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M. 2002. The structure of haplotype blocks in the human genome. Science 296(5576):2225-2229.
19. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. 1993. The economic burden of depression in1990. J Clin Psychiatry 54(11):405-418.
20. Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
21. Hong CJ, Chen TJ, Yu YW, Tsai SJ. 2006. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 6(1):27-33.
22. Kapur S, Remington G. 1996. Serotonin-Dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry 153:466-476.
23. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J. 2006. Effects of the serotonin Type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53(4):186-195.
24. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, Hirose T, Nanko S. 1997. Serotonin transporter gene polymorphisms: Ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 2(6):457-462.
25. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. 2004. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 7(4):501-506.
26. Lemonde S, Turecki G, Bakish D, Du L, Hrdina P, Bown C, Sequeira A, Kushwaha N, Morris S, Basak A. 2003. Impaired trans-repression at a 5-HT1A receptor gene polimorphism associated with major depression and suicide. J Neurosci 23(25):8788-8799.
27. Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Johnson JA, Millard WJ. 2007. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 11(3):155-160.
28. Li Q, Wichems C, Heils A, Lesch KP, Murphy DL. 2000. Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: Gender and brain region differences. J Neurosci 20(21):7888-7895.
29. Mitchell AJ. 2006. Two-week delay in onset of action of antidepressants: New evidence. Br J Psychiatry 188:105-106.
30. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. 2006. Higher 5-HT(1A) receptor binding potential during a major depressive episode predicts poor treatment response: Preliminary data from a naturalistic study. Neuropsychopharmacology 31(8):1745-1749.
31. Parsey RV, Oquendo MA, Simpson NR, Ogden RT, Van Heertum R, Arango V, Mann JJ. 2002. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res 954(2):173-182.
32. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA. 2000. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23(5):587-590.
33. Posternak MA, Zimmerman M. 2005. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66(2):159-166; quiz 147, 273-274.
34. Quitkin FM, Rabkin JG, Ross D, Stewart JW. 1984. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 41(8):782-786.
35. Sartorius N. 2001. The economic and social burden of depression. J Clin Psychiatry 62(Suppl 15):8-11.
36. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. 2004. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: Preliminary findings. Int J Neuropsychopharmacol 7(4):453-460.
37. Serretti A, Artioli P, Quartesan R. 2005. Pharmacogenetics in the treatment of depression: Pharmacodynamic studies. Pharmacogenet Genomics 15(2):61-67.
38. Serretti A, Kato M, De Ronchi D, Kinoshita T. 2007a. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12(3):247-257.
39. Serretti A, Mandelli L, Giegling I, Schneider B, Hartmann AM, Schnabel A, Maurer K, Moller HJ, Rujescu D. 2007b. HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. Am J Med Genet Part B 144B(3):291-299.
40. Serretti A, Mandelli L, Giegling I, Schneider B, Hartmann AM, Schnabel A, Maurer K, Moller HJ, Rujescu D. 2007c. HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. Am J Med Genet Part B 144B(3):291-299.
41. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. 1998. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3(6):508-511.
42. Stahl S. 1994. 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 30(1):39-43.
43. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P. 1998. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 55(4):334-343.
44. Suzuki Y, Sawamura K, Someya T. 2004. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 4(4):283-286.
45. Ustun TB. 2001. The worldwide burden of depression in the 21st century. In: Weismann MM, editor. Treatment of depression: Bridging the 21st Century. Washington, DC: American Psychiatric Press. pp 35-45.
46. Wittchen H-U, Jacobi F. 2005. Size and burden of mental disorders in Europe - A critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15(4):357-376.
47. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. 2006. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol.